In vivo neurochemical effects induced by changes in endocannabinoid neurotransmission

被引:23
作者
Degroot, Aldemar
Nomikos, George G. [1 ]
机构
[1] Amgen Inc, Cambridge Res Ctr, Neurosci, Cambridge, MA 02139 USA
[2] Ventana Clin Res Corp, Toronto, ON, Canada
关键词
D O I
10.1016/j.coph.2006.11.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Neurotropic effects of endo- and exo-cannabinoids are largely caused by their effects on classical neurotransmitter signaling. Pharmacological and molecular tools have been used to selectively target the endocannabinoid system. Endocannabinoids mostly act as retrograde messengers and, upon release from postsynaptic neurons, they modulate neurotransmitter release by activating presynaptic cannabinoid receptors. Generally, increased and decreased endocannabinoid neurotransmission results in decreases and increases in neurotransmitter release, respectively. However, net effects are often pleiotropic, probably owing to the level of regional endogenous tone, transsynaptic mechanisms and cumulative actions. Changes in classical neurotransmitter function can, in turn, modulate endocannabinoid signaling. Importantly, the endocannabinoid system can be altered in response to physiological and pathogenic events and targeted for therapeutic intervention.
引用
收藏
页码:62 / 68
页数:7
相关论文
共 55 条
[31]   Anandamide enhances extracellular levels of adenosine and induces sleep: An in vivo Microdialysis study [J].
Murillo-Rodriguez, E ;
Blanco-Centurion, C ;
Sanchez, C ;
Piomelli, D ;
Shiromani, PJ .
SLEEP, 2003, 26 (08) :943-947
[32]   Effects of chronic Δ9-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze [J].
Nava, F ;
Carta, G ;
Colombo, G ;
Gessa, GL .
NEUROPHARMACOLOGY, 2001, 41 (03) :392-399
[33]   The relationship of in vivo central CB1 receptor occupancy to changes in cortical monoamine release and feeding elicited by CB1 receptor antagonists in rats [J].
Need, AB ;
Davis, RJ ;
Alexander-Chacko, JT ;
Eastwood, B ;
Chernet, E ;
Phebus, LA ;
Sindelar, DK ;
Nomikos, GG .
PSYCHOPHARMACOLOGY, 2006, 184 (01) :26-35
[34]  
Onaivi ES, 2006, METH MOLEC MED, V123, P291
[35]   Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex [J].
Oropeza, VC ;
Page, ME ;
Van Bockstaele, EJ .
BRAIN RESEARCH, 2005, 1046 (1-2) :45-54
[36]   Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity [J].
Patel, S ;
Rademacher, DJ ;
Hillard, CJ .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2003, 306 (03) :880-888
[37]  
Pertwee RG, 2005, HANDB EXP PHARMACOL, V168, P1
[38]   Modulation of Δ9-THC-induced increase of cortical and hippocampal acetylcholine release by μ opioid and D1 dopamine receptors [J].
Pisanu, A. ;
Acquas, E. ;
Fenu, S. ;
Di Chiara, G. .
NEUROPHARMACOLOGY, 2006, 50 (06) :661-670
[39]   Δ9-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex:: an in vivo microdialysis study [J].
Pistis, M ;
Ferraro, L ;
Pira, L ;
Flore, G ;
Tanganelli, S ;
Gessa, GL ;
Devoto, P .
BRAIN RESEARCH, 2002, 948 (1-2) :155-158
[40]   Molecular Biology of the Enzymes that Degrade Endocannabinoids [J].
Puffenbarger, Robyn A. .
CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2005, 4 (06) :625-631